June 30, 2021 | Portfolio News

CVRx, Inc. Announces Upsized Pricing of Initial Public Offering

20

Novel FDA PMA & de novo 510k approvals

55

U.S. Commercial Product Launches

39

Level I Clinical Trials

29

Strategic Financings

30

Exits by IPO or M&A